← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Artery Therapeutics, Inc.
San Ramon, CA
$8,291,590
Total funding
3
Grants
Funding over time
peak $2.5M · FY2019–25$2.5M$1.9M$1.3M$625K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,291,590 · 3
By mechanism
R44$8,291,590 · 3
Investigators at Artery Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253$2,482,205
R44 · FY2023 · AG
Manufacturing of ABCA1 agonist small molecule peptide CS6253 to support chronic toxicology studies in Wistar rats and Cynomolgus monkeys$2,454,521
R44 · FY2025 · AG
CS6253 development for the treatment of apoE4 driven dementia includingAlzheimer's disease$2,375,985
R44 · FY2020 · AG
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253$499,197
R44 · FY2021 · AG
CS6253 development for the treatment of apoE4 driven dementia includingAlzheimer's disease$479,682
R44 · FY2019 · AG